Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Stock Chart & Stats
$9.89
-$0.83(-1.65%)
At close: 4:00 PM EST
$9.89
-$0.83(-1.65%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume45.38K
Average Volume (3M)7.82M
Market Cap
$684.70M
Enterprise Value$2.64B
Total Cash (Recent Filing)$425.08M
Total Debt (Recent Filing)$75.77M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 18, 2025EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding63,501,404
10 Day Avg. Volume10,243,112
30 Day Avg. Volume7,815,878
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)7.62
Price to Sales (P/S)0.00
P/FCF Ratio-29.07
Enterprise Value/Market Cap3.86
Enterprise Value/Revenue25.94K
Enterprise Value/Gross Profit-2.40K
Enterprise Value/Ebitda-14.57
Forecast
1Y Price Target
$17.92Price Target Upside81.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Efficacy DifferentiationDifferentiation in efficacy, such as better treatment outcomes in more severe patients, could help market adoption of sonelokimab.
Market PotentialThe commercial opportunity for sonelokimab (SLK) in HS should be significant, translating to sales that far exceed peak revenue projections.
Safety ProfileSLK continued to show a favorable safety profile with no new safety signals detected, including an absence of key events of interest such as suicidal ideation and behavior.
Bears Say
Competitive ChallengesFrom a commercial standpoint, VELA appears undifferentiated and potentially inferior compared to Bimzelx, indicating competitive challenges.
Financial ConstraintsMoonlake now faces a financing hurdle — MLTX shares have traded down to near cash (less debt).
Regulatory ConcernsSignificant regulatory risk for sonelokimab given VELA-2 missed statistical significance on the primary statistical analysis.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $684.70M.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 33 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Aug 05, 2025. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.74 by -$0.13.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.88.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 63,501,404 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.74. Following the earnings report the stock price went up 0.169%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
MoonLake Immunotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.92 (81.19% Upside)
$17.92 (81.19% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 7.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $46.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 36.5%
Last 30 Days ▲ 36.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.26%
12-Months-Change
Fundamentals
Return on Equity
-40.29%
Trailing 12-Months
Asset Growth
-15.56%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (MLTX) is a biotechnology company focused on developing innovative therapies for inflammatory diseases. The company leverages its proprietary nanobody technology to create targeted, potent, and effective treatments aimed at improving patient outcomes. MoonLake's core products include a pipeline of therapeutic candidates designed to address conditions such as dermatological, rheumatological, and gastroenterological diseases.
MLTX Stock 12 Month Forecast
Average Price Target
$17.92
▲(81.19% Upside)
Technical Analysis
Protagonist Therapeutics
―
Zai Lab
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
Ownership Overview
45.00% Insiders
16.16% Mutual Funds
0.15% Other Institutional Investors
38.07% Public Companies and Individual Investors